Xintela receives 'intention to grant' decision from European Patent Office for stem cell product XSTEM

Lund, Sweden, 29 October 2020 - Xintela announced today that the European Patent Office (EPO) has issued an "Intention to grant" decision for the patent application covering the company's stem cell product XSTEM®, consisting of integrin 10-selected mesenchymal stem cells.

Using its unique marker technology and stem cell selection method, Xintela has developed a stem cell platform, XSTEM, for stem cell-based products. The company's first focus is treatment of osteoarthritis in the knee and is preparing to start clinical studies in 2021. XSTEM is also being evaluated in a preclinical model for the treatment of ARDS (Acute Respiratory Distress Syndrome), a lung complication that affects seriously ill covid-19 patients.

The company's European patent application no. 18703531.6, covering integrin 10-selected mesenchymal stem cells, has now received an intention to grant communication from the EPO. This means the EPO will grant the patent after fulfillment of certain administrative steps. The granted patent will confer protection for Xintela's stem cell product XSTEM in Europe until 2038. In addition to product protection, the patent also protects the use of XSTEM for the prevention and treatment of degenerative joint diseases such as osteoarthritis, bone sclerosis and degenerative disc disease (DDD) as well as traumatic cartilage and bone injuries.

- This is fantastic news that adds huge value to Xintela's stem cell business. A product patent that protects the stem cell product XSTEM, combined with our own GMP production facility, secures the development and commercialization of stem cell therapies from our stem cell platform for years to come, says Xintela's CEO Evy Lundgren-Åkerlund.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication on the 29th of October, 2020.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela
Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Nerladdningsbara filer

Kommuniké från Xintelas årsstämma 2021

Lund, Sverige, 7 maj 2021 - Idag hölls årsstämma i Xintela AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet.


Targinta rekryterar Per Norlén som VD

Lund, Sverige, den 4 maj 2021 - Xintela meddelar idag att Per Norlén har rekryterats som VD för Xintelas helägda dotterbolag Targinta inom onkologi. Han tillträder 1 september 2021. Per Norlén kommer även ha rollen som Xintelas Chief Medical Officer (CMO/Medicinsk Chef) från 1 juli 2021. Rekryteringen är ett viktigt steg i processen med att knoppa av Targinta som ett fristående bolag.


Targinta recruits Per Norlén as CEO

Lund, Sweden, May 4, 2021 - Xintela announces today that Per Norlén has been recruited as CEO of Xintela's wholly owned oncology subsidiary Targinta. He will start on 1 September 2021. Per Norlén will also have the role of Xintela's Chief Medical Officer (CMO) from 1 July 2021. The recruitment is an important step in the process of spinning out Targinta as an independent company.


Xintela offentliggör årsredovisning för 2020

Lund, Sverige, 16 april 2021 - Xintela AB (publ) meddelar idag att bolaget publicerar årsredovisningen för 2020. Årsredovisningen finns tillgänglig på bolagets hemsida www.xintela.se samt via bifogad PDF.


Inspektion av Xintelas GMP-verksamhet för tillverkningstillstånd genomförd

Lund, Sverige, den 12 april 2021 - Xintela meddelar idag att Läkemedelsverket har genomfört en inspektion för tillstånd att producera cellterapiprodukter, så kallade avancerade terapiläkemedel (ATMPs), för kliniska studier.


Xintela GMP inspection for manufacturing license completed

Lund, Sweden, 12 April 2021 - Xintela announces today completion of the inspection by the Swedish Medical Products Agency for a license to produce cell therapy products, also known as Advanced Therapy Medicinal Products (ATMPs), for clinical studies.


KALLELSE TILL ÅRSSTÄMMA I XINTELA AB (PUBL)

Aktieägarna i Xintela AB (publ), org. nr. 556780-3480, kallas härmed till årsstämma den 7 maj 2021 kl. 09.00 i Medicon Village, Scheeletorget 1, hus 601, i Lund.


Xintela rapporterar positiva resultat från preklinisk ARDS studie och erhåller nytt anslag om 2,3 miljoner kronor

Lund, Sverige, 6 april, 2021 - Xintela meddelar idag positiva resultat från den prekliniska ARDS (Acute Respiratory Distress Syndrome) studien som delfinansierats av Vinnova. Resultaten från studien visar potentialen av bolagets stamcellsprodukt XSTEM® för behandling av ARDS, en livshotande lungkomplikation som bl.a. kan drabba svårt sjuka covid-19 patienter. Xintela meddelar också att bolaget har erhållit ett nytt bidrag från Swelife/Vinnova för att fortsätta undersöka verkningsmekanismer av XSTEM i ARDS modellen och förbereda XSTEM för kliniska studier.


Xintela reports positive results from preclinical ARDS study and new grant of 2.3 million SEK

Lund, Sweden, 6 April 2021 - Xintela today announces the positive outcome of the preclinical ARDS (Acute Respiratory Distress Syndrome) study partly financed by Vinnova. The results of the study demonstrate the potential of the company's stem cell product XSTEM® in the treatment of ARDS, a life-threatening lung complication that can affect severely ill COVID-19 patients. Xintela also announces a new grant from Swelife/Vinnova to further investigate the mechanism of action of XSTEM in the preclinical ARDS model and to prepare XSTEM for clinical studies.


Xintela erhåller tillstånd för vävnadsinrättning

Lund, Sverige, 19 mars 2021 - Xintela meddelar idag att bolaget har erhållit tillstånd för vävnadsinrättning från Läkemedelsverket för hantering av humana vävnader och celler avsedda för framställning av läkemedel.


Xintela gets tissue establishment license

Lund, Sweden, 19 March 2021 - Xintela announces today that the company has received a tissue establishment license from the Swedish Medical Products Agency for handling human tissues and cells for manufacturing medicinal products.


Xintela erhåller godkänt patent i Europa för sin stamcellsprodukt XSTEM

Lund, Sverige, 17 mars 2021 - Xintela meddelar att Europapatentverket (EPO) idag har godkänt patentansökan avseende bolagets stamcellsprodukt XSTEM® bestående av integrin α10β1-selekterade mesenkymala stamceller.


Xintela gets patent grant in Europe for XSTEM stem cell product

Lund, Sweden, 17 March 2021 - Xintela announces that the European Patent Office (EPO) has today approved the patent application for the company's stem cell product XSTEM® consisting of integrin 10-selected mesenchymal stem cells.


Xintela publicerar antikroppsresultat från glioblastomstudie

Lund, Sverige, 12 mars 2021 - Xintela meddelar att resultaten från bolagets prekliniska glioblastomstudie med funktionsblockerande antikroppar idag har publicerats i den välrenomerade internationella vetenskapliga tidskriften Cancers. Publikationen visar bland annat att antikroppar riktade mot bolagets målmolekyl integrin 101 signifikant minskar tillväxt av den mycket aggressiva hjärntumören glioblastom i en djurmodell.


Xintela publishes results from glioblastoma antibody study

Lund, Sweden, March 12, 2021 - Xintela announces that the results of the company's preclinical glioblastoma study with function-blocking antibodies have today been published in the renowned international scientific journal Cancers. The publication shows, among other things, that antibodies directed to the company's target molecule integrin 101 significantly reduce the growth of the aggressive and deadly brain tumor glioblastoma in an animal model.


Bokslutskommuniké 2020-01-01 till 2020-12-31

Sammanfattning av bokslutskommuniké


Year-end report 1 Jan - 31 Dec 2020

Summary of the year-end report


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90

Om beQuoted